

1 **Title page**

2

3 **No decline in hepatitis C virus incidence among HIV-positive men who have**
4 **sex with men (1990-2014)**

5

6 **Authors:**

7 Daniela Katinka VAN SANTEN¹, Jannie Johanna VAN DER HELM¹, Julia DEL
8 AMO², Laurence MEYER³, Antonella D'ARMINIO MONFORTE⁴, Matt PRICE^{5,6},
9 Charles Antoine BÉGUELIN⁷, Robert ZANGERLE⁸, Mette SANNES⁹, Kholoud
10 PORTER¹⁰, Ronald Bertus GESKUS^{1*} & Maria PRINS^{1,11*}, on behalf of the
11 CASCADE Collaboration in EuroCoord

12

13 **Affiliations:**

14 1. Department of Infectious Disease Research and Prevention, Public Health Service
15 of Amsterdam, Amsterdam, the Netherlands

16 2. National Centre of Epidemiology, Instituto de Salud Carlos III (Madrid) and
17 CIBERESP, Spain

18 3. Faculte de Medecine Paris Sud, Le Kremlin Bicetre, France; INSERM U1018,
19 Centre de
20 recherche en Epidemiologie et Sante des Populations, Universite Paris Sud, Le
21 Kremlin Bicetre, France

22 4. Department of Health Sciences, Clinic of Infectious and Tropical Diseases, S
23 Paolo Hospital, University of Milan, Milan, Italy.

24 5. International AIDS Vaccine Initiative, New York City, New York

1 6. Department of Epidemiology and Biostatistics, University of California, San
2 Francisco, California, USA

3 7. Department of infectious Diseases, Bern University Hospital, University of Bern
4 Switzerland

5 8. Department of Dermatology and Venereology, Medical University of Innsbruck,
6 Innsbruck, Austria

7 9. Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway

8 10. Research Department of Infection and Population Health, University College
9 London, London, United Kingdom

10 11. Department of Infectious Diseases, Center for Infection and Immunology
11 Amsterdam (CINIMA), Academic Medical Center (AMC), Amsterdam, the
12 Netherlands

13 * Maria Prins and Ronald Geskus contributed equally as senior coauthors.

14

15 **Corresponding author:**

16 Daniela K. van Santen

17 Nieuwe Achtergracht 100

18 1018 WT

19 Amsterdam, the Netherlands

20 M: dvsanten@ggd.amsterdam.nl

21 T: +31205555231

22

Abbreviations

| | |
|---------|--|
| HCV | Hepatitis C Virus |
| HIV | Human immunodeficiency virus |
| MSM | Men who have sex with men |
| CASCADE | Concerted Action on SeroConversion to AIDS and Death in Europe |
| STIs | Sexually transmitted infections |
| AIC | Akaike Information Criterion |
| cART | Combination antiretroviral therapy |

Word count: 5,997

Number of Figures: 5

Number of Tables: 1

Conflicts of Interest and Source of Funding:

Funding: The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement n° 260694

Conflict of interest:

Kholoud Porter has served on the Dolutegravir Advisory Board.

Author's contribution:

DvS performed the statistical analyses together with RG, also interpreted the data, and wrote the manuscript. JvdH provided substantial contributions to the analyses and interpretation of the data as well as the manuscript. MP and RG designed and supervised the overall study, and substantially contributed to the analyses,

1 interpretation of the data and manuscript. KP obtained funding for the study. All
2 authors contributed to the design, additional HCV testing, interpretation of the data,
3 subsequent drafts and approved the final version of the manuscript.

1 **Abstract**

2 **Background and aims:** Hepatitis C virus (HCV) incidence among HIV-positive men
3 who have sex with men (MSM) has increased since 2000, though regional
4 differences have been documented in recent years. We aimed to 1) estimate trends
5 in HCV incidence among HIV-positive MSM, 2) assess the association between
6 incidence and geographical region, age and HIV-related measurements and, 3)
7 assess temporal changes in time from HIV seroconversion to HCV infection.

8
9 **Methods:** We used data from MSM with well-estimated dates of HIV seroconversion
10 from the CASCADE Collaboration (1990-2014). We allowed for smoothly varying
11 trends in HCV incidence over calendar time using restricted cubic splines. We
12 assessed the association of calendar year, age, CD4 count (lagged), HIV RNA
13 (lagged), geographical region and HIV infection stage (recent vs. chronic) with HCV
14 incidence using Poisson regression.

15
16 **Results:** Of 5,941 MSM, 337 acquired HCV during follow-up. HCV incidence
17 significantly increased from 0.7/1000 person-years (py) in 1990 to 18/1000 py in
18 2014. Recent calendar years, younger age, recent HIV infection and higher HIV RNA
19 levels were significantly associated with HCV incidence, while CD4 count was not.
20 Trends differed by geographical region; while incidence appears to have stabilized in
21 Western Europe and remained stable in Southern Europe, it continued to increase in
22 Northern Europe in recent years. Time from HIV to HCV infection significantly
23 decreased over calendar time ($p<0.001$).

1 **Conclusions:** HCV has continued to spread among HIV-positive MSM in recent
2 years, but trends differ by geographical region. Interventions to decrease the risk of
3 HCV acquisition and increase early diagnosis are warranted.

4
5 **Lay summary:** Hepatitis C virus infection continues to spread among HIV-positive
6 men who have sex with men, especially among younger individuals. However, trends
7 seem to differ by European region in recent years. Furthermore, men who have sex
8 with men with a higher HIV RNA load were more likely to get infected with the
9 hepatitis C virus. During recent HIV infection, MSM appear to be at higher risk of
10 acquiring hepatitis C.

11
12 **Word count abstract:** 252

13
14 **Keywords:** Hepatitis C, incidence, HIV seroconverters, men who have sex with
15 men, HIV RNA

1 Introduction

2
3
4 Since 2000, hepatitis C virus (HCV) incidence has increased among HIV-positive
5 men who have sex with men (MSM) [1,2]. Using data from the CASCADE
6 Collaboration (Concerted Action on SeroConversion to AIDS and Death in Europe) in
7 EuroCoord, we previously showed that HCV incidence increased in MSM with well-
8 estimated HIV seroconversion dates after 1990, but the main expansion of the HCV
9 epidemic was observed from 2002 until 2007, the censoring date of the analysis [1].
10 A recent meta-analysis showed that HCV incidence has continued to increase, with
11 an estimated pooled incidence of 13/1000 person-years (py) in 2010 to an
12 extrapolated incidence estimate of 19/1000 py in 2015 [2]. However, other studies
13 have shown varying trends in HCV incidence among MSM over the past years [3,4].
14 In Amsterdam, the Netherlands, HCV incidence seems to be stabilizing [3], whereas
15 in Switzerland an increasing incidence among MSM has been observed [4].
16
17 A number of factors such as fisting, the presence of sexually-transmitted infections
18 (STIs), use of recreational drugs, and condomless anal intercourse have been
19 shown to be significantly associated with acute HCV infection [4-10]. In addition, one
20 study from the US reported that older age was independently associated with an
21 acquired HCV infection [10], whereas another study from the Netherlands reported
22 that younger MSM had a higher risk [3]. As acute HCV infections are predominantly
23 found among HIV-positive MSM, it has been suggested that HIV facilitates sexual
24 transmission of HCV [11]. However, contrasting results on the association between
25 CD4⁺ T-cell count (CD4 count) and HCV incidence have been reported [4,9,10,12].
Additionally, few studies have investigated the association with HIV RNA and, those

1 that have, either dichotomized HIV RNA and/or could only assess the association in
2 univariable analyses [4,9,12]. The role that HIV-related factors play in the spread of
3 HCV among HIV-positive MSM is currently still being debated.

4
5 Using data among MSM with well-estimated dates of HIV seroconversion from the
6 CASCADE Collaboration we aimed to 1) update trends in HCV incidence; overall
7 and by geographical region, 2) assess the associations between HCV incidence and
8 HIV-related measurements, geographical region, age and calendar year, and 3)
9 assess whether the time interval between HIV seroconversion and HCV infection has
10 changed over calendar time.

1 **Methods**

2 We used data from 16 out of 28 cohorts from the CASCADE Collaboration across
3 Europe, Australia and Canada. Of the excluded cohorts, 5 were non-MSM cohorts
4 and 6 cohorts had tested less than 50% of MSM for HCV and could not provide
5 stored samples for HCV testing (missing HCV status data from 57.2% to 96.2%)
6 (Fig. 1). The Kenyan cohort (IAVI; n=92) was also excluded as we believe that the
7 HCV epidemic among MSM in Kenya differs from that in high-income countries (no
8 incident HCV infections were observed). All cohorts include data from HIV-positive
9 individuals with dates of HIV seroconversion that could be reliably estimated based
10 on the midpoint between the last HIV-negative and first HIV-positive test (at most 36
11 months apart) or, evidence of acute HIV infection. Details of CASCADE have been
12 previously described [13]. We included only men from the 16 cohorts who were
13 recorded as having acquired HIV through sex between men and whose potential HIV
14 transmission route excluded injecting drug use. For all cohorts, we used all available
15 data, except for MSM from the French PRIMO cohort who were censored at the 31st
16 of December 2005 as routine HCV testing was only recorded until that year. All
17 collaborating cohorts received approval from their regulatory or national ethic boards
18 (see Appendix) and informed consent was obtained for all participants.

19
20 HCV negative status throughout follow-up was based on at least one HCV-negative
21 test result and never testing HCV positive. HCV infection was based on any positive
22 HCV test (RNA, antibodies and/or antigen). Among MSM who acquired HCV during
23 follow-up, the date of HCV infection was estimated as the midpoint between the last
24 HCV-negative and first HCV-positive test. To optimize testing frequency, we
25 performed additional HCV testing in cohorts that had stored specimens (8 cohorts).

1 Stored samples from HCV-negative MSM were tested using a sample closest to the
2 date of their last clinic visit if more than 2 years had elapsed since their last HCV-
3 negative test date. For HCV-positive MSM without a previous HCV-negative test
4 date, the sample closest to HIV seroconversion but up to one year of it was tested to
5 assess whether they had become HCV infected during follow-up; if HCV negative,
6 midpoint samples were tested until the HCV seroconversion interval was a maximum
7 of 2 years. For MSM with a recorded HCV infection during follow-up but with an HCV
8 test interval >2 years, samples with dates which fell in the interval between their last
9 HCV-negative and first HCV-positive test date were tested. All cohorts provided a
10 date of start of routine HCV testing (defined by testing of all MSM for HCV according
11 to prevailing guidelines or practices) and details on HCV testing strategies (e.g.,
12 retrospective testing).

13 **HCV incidence**

14 We estimated overall HCV incidence trends between 1990 and 2014 and stratified
15 by European geographical region between 1997 until 2013 as not all regions have
16 available data for the total study period. Geographical region was defined based on
17 the United Nations classification criteria [14], namely Western (the Netherlands,
18 Switzerland, France, Austria and Germany), Northern (United Kingdom and Norway),
19 and Southern Europe (Italy, Spain and Greece), North America (Canada) and
20 Australia and New Zealand (Australia) (Table 1). We only illustrate HCV incidence by
21 geographic region for the three European regions as Canada and Australia had
22 relatively small numbers of MSM and few HCV infections were observed. MSM were
23 considered at risk from the latest of: HIV seroconversion, routine HCV testing date
24 per cohort or enrolment in the cohort (Table 1). We used two methods to calculate
25

1 follow-up time as previously described [1]. In both methods, MSM with one or more
2 HCV-positive tests but without a previous HCV-negative test were excluded (Fig. 1).
3 In method 1, follow-up time began from the moment MSM were considered at risk
4 and will likely underestimate HCV incidence as some of the excluded MSM, who only
5 had HCV-positive tests under active follow-up, could have become infected between
6 the moment they were considered at risk and their first HCV test. Appreciating this
7 possible underestimation, we applied another method (method 2) where follow-up
8 began from the first HCV-negative test after becoming at risk (i.e., left truncation).
9 This approach, however, leads to a shorter follow-up time for MSM who remained
10 HCV-negative throughout follow-up as they are less likely to have been tested
11 retrospectively compared to MSM who became HCV-positive. Consequently, this
12 method is likely to overestimate HCV incidence. In both methods follow-up was
13 calculated until the last HCV-negative date or, in case of HCV infection, the midpoint
14 date. Only the first observed HCV infection during follow-up within an individual was
15 included in the analyses. We used Poisson regression models where HCV incidence
16 was allowed to vary smoothly over calendar time using restricted cubic splines for
17 the overall and the stratified analyses (i.e., by geographical region). We performed a
18 sensitivity analysis using an interval-censored approach as previously described [2]
19 (Supplementary text 1).

20 21 **HCV risk factor analyses**

22 We used three Poisson regression models that included calendar year using the
23 method 1 approach to calculate follow-up. We assessed variation of HCV incidence
24 by geographical region (model 1) and the associations with age (model 2), and HIV-
25 related measurements: CD4 count, HIV RNA and HIV infection stage (model 3). All

continuous variables were included as restricted cubic splines (calendar year, current age, \log_{10} HIV RNA and cube root CD4 count). The knots were chosen based on the 2.5, 25, 50, 75 and 97.5 percentiles.

Model 1

We compared the fit of three submodels by means of the Akaike information criterion (AIC) - model 1.1=calendar year only, model 1.2=calendar year and region as main effects, model 1.3=calendar year, region, and their interaction.

Model 2

We then added age to the best fitting model 1. In this model, we tested the interaction between age and both region and calendar year. Significant interactions were included in this model.

Model 3

This multivariable model included: age, calendar year, region, HIV RNA and CD4 count. The CD4 count and HIV RNA value from the previous visit were used, but had to be no more than one year before. Missing HIV RNA and CD4 count data were imputed based on individual predicted values from random-effects models adjusted for age and stratified by combination antiretroviral therapy (cART) use: treatment naïve, on cART, and during cART interruption among cART-experienced (Supplementary text 2). For this model we defined a treatment interruption as a stop of cART for >1 week. When a person had no CD4/HIV RNA values throughout follow-up, we used the predicted values based on the fixed effects. We defined cART as a 3 drug ART regimen containing 2 different classes, or 3 nucleoside reverse transcriptase inhibitors (NRTIs), provided Tenofovir or Abacavir were included in the regimen. In additional analyses we assessed whether a recent HIV infection (defined as the period from estimated HIV seroconversion to less than 0.7 years hereafter)

1 was associated with HCV incidence using model 3. We also tested the interaction
2 between HIV RNA and HIV infection stage (recent vs. chronic). We used the
3 likelihood ratio test to test significance in model 2 and 3. Instead of reporting
4 incidence ratios, we illustrate the association between age, CD4 count and HIV RNA
5 and incidence by plotting the absolute incidence with 95% confidence intervals,
6 choosing representative values (e.g., median values) for the other covariates.

8 **Sensitivity analyses**

9 We performed four sensitivity analyses. As we imputed missing CD4 and HIV RNA
10 values, first, we performed the analyses using predicted values instead of using a
11 combination of predicted and observed values. Second, we performed a complete
12 case analyses in which only observed values were included. Third, an analysis was
13 performed where the antepenultimate CD4 count and HIV RNA value were used.
14 The reason for the third analysis is that antibody development might be delayed in
15 HIV-positive individuals [15,16] and in our study 83.4% (n=281) of HCV infections
16 were based on HCV antibody seroconversion and 15.7% (n=53) were based on a
17 positive HCV RNA test and an HCV-antibody negative test result. Lastly, although
18 additional HCV testing was performed in the Italian cohort (ICoNA), we performed
19 the overall HCV incidence analyses without this cohort as currently there is no
20 routine HCV testing in place.

1 **Time from HIV to HCV**

2 Kaplan-Meier curves were constructed applying the method 1 follow-up calculation to
3
4 compare cumulative HCV incidences by calendar period of HIV seroconversion. We
5
6 modelled whether HCV incidence depended on calendar year using a Cox
7
8 proportional hazards model, including calendar year of HIV seroconversion as a
9
10 continuous variable using restricted cubic splines.
11
12
13
14
15
16

17 7

18 8 Statistical analyses were performed using R [17] and Stata [18] software.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

6 9

10 10

Results

Of 17,429 HIV-positive MSM, 7,368 MSM were excluded from 6 cohorts with more than 50% missing HCV status data and that could not provide stored samples for HCV testing (Fig. 1). Of the remaining 10,061 MSM, 9,014 had at least one HCV test result of whom 8,311 tested only HCV negative and 703 had at least one HCV-positive test result. MSM with HCV test results did not differ by age or ethnicity from MSM without test results, but were more likely to have a post-secondary education (37% vs. 32%). The median and mean number of HCV tests during follow-up among cohorts that routinely and prospectively collected HCV data (n=13) was 3.0 (Interquartile range (IQR)=2-6) and 4.1 (Standard deviation=3.6), respectively. A total of 7,864 MSM had follow-up and at least one HCV test result (Table 1). Among these MSM, 57.0% were white and median age was 34 years (IQR=28-41) at inclusion. The median year of HIV seroconversion was 2004 (IQR=1999-2008). Over the total study period, the median observed CD4 count was 509 cells/ μ L (IQR=367-684), median observed HIV RNA was 70 copies/mL (IQR=50-15522) and 70.3% started or were on cART.

A total of 5,941 and 4,326 MSM were eligible according to method 1 and 2, respectively (Fig. 1; Table 1). These MSM accounted for a total of 28,600 and 19,480 person-years and 337 and 279 HCV infections in method 1 and 2, respectively. The median follow-up time was 4.0 (IQR=1.7-7.2) and 3.9 (IQR=2.0-6.3) years in method 1 and 2, respectively. Of the 337 incident HCV infection observed during follow-up, 25 (7.4%) occurred during recent HIV infection.

HCV incidence

HCV incidence significantly increased from 1990 onwards ($p_{method1} < 0.001$; $p_{method2} = 0.04$); with an estimated incidence ranging from: 0.7/1000 py (95% confidence interval (CI)=0.1-5) in 1990 to 18/1000 py (95%CI=9-37) in 2014 in method 1 and from 3/1000 py (95%CI=0.4-18) in 1990 to 21/1000 py (95%CI=10-42) in 2014 in method 2 (Fig. 2). The interval-censored method showed a similar increasing trend (Supplementary Fig. 1). Excluding one cohort (ICoNA) from the overall analyses, led to similar statistically significant increasing trends by both methods, although the estimations were slightly lower (Supplementary Fig. 2). The stratified analyses by geographical region showed that in recent years HCV incidence seems to have increased in Northern Europe, but calendar year was only statistically significant in method 2 ($p = 0.02$) (Fig. 3). In Southern Europe, a stable trend was observed and calendar year was not significant. In Western Europe the trend was significant in both methods ($p_{method1} = 0.001$; $p_{method2} = 0.005$); based on method 1, HCV incidence increased sharply from 14/1000 py (95%CI=10-20) in 2006 to 23/1000 py (95%CI=17-31) in 2009, but declined thereafter to 9/1000 py (95%CI=3-27) in 2013 (Fig. 3).

HCV risk factor analyses

The first analysis showed that the model with region and calendar year as main effects only (model 1.2) had the lowest AIC of the three submodels, thus the best fit.

The second model showed that younger HIV-positive MSM had a higher risk of HCV infection ($p = 0.005$) (Fig. 4A). The interaction term between age and region was

1 borderline significant ($p=0.05$). Based on the model with the interaction term, in
2 Western Europe, HCV incidence remained highest and stable until around age 35
3 and declined thereafter (Supplementary Fig. 3). In Northern and Southern Europe,
4 HCV incidence increased until age 35, and declined thereafter.

5 In the third model, a higher HIV RNA was associated with higher HCV incidence
6 ($p=0.001$) (Fig. 4C), especially when \log_{10} HIV RNA was ≥ 5 copies/mL, whereas
7 CD4 count (Fig. 4B) was not ($p=0.53$). When we added “HIV infection stage” to the
8 model, the association between HIV RNA and HCV incidence was attenuated
9 ($p=0.01$) (Fig. 4D). HCV incidence was higher during recent HIV infection than during
10 chronic HIV infection (Incidence Rate Ratio_{recent vs. chronic}=1.8, 95%CI=1.1-2.7,
11 $p=0.02$). The interaction term between HIV infection stage and HIV RNA was not
12 significant ($p=0.60$), and was left out of the model. The association with CD4 count
13 remained non-significant ($p=0.53$).

14 15 **Sensitivity analyses**

16 All sensitivity analyses showed comparable associations of HIV RNA, CD4 count
17 and calendar year with HCV incidence and the conclusions were not altered.
18 However, in the complete case analyses, HIV RNA was non-significant ($p=0.25$)
19 (Supplementary Fig. 4).

20 In the model that included HIV infection stage, two sensitivity analyses (i.e.,
21 antepenultimate and predicted values) showed comparable associations between
22 HIV RNA and HCV incidence, but when antepenultimate HIV RNA values were used,

1 the association was no longer statistically significant (p=0.09). In the complete case
2 analyses, there was no association (p=0.40).

3

4 **Time from HIV to HCV**

5 Among 5,680 MSM who seroconverted for HIV at or after 1990, median time from
6 HIV seroconversion to HCV infection was 5.2 years. The time from HIV
7 seroconversion until HCV infection significantly decreased over calendar periods
8 ($p_{\log\text{-rank}} < 0.001$). At 3 years after HIV seroconversion, the cumulative HCV incidence
9 was 5.9% (95%CI=3.8-9.2%) in 2010-2014 compared to 2.0% (95%CI=0.5-7.8%) in
10 1990-1994 (Fig. 5). The Cox model showed that MSM who seroconverted for HIV in
11 2010, had a 6.1 (95%CI=2.8-13.3) times higher hazard of acquiring HCV than MSM
12 who seroconverted in 1990 ($p < 0.001$) (Supplementary Fig. 5).

13

Discussion

Using data from the CASCADE Collaboration among HIV-positive MSM with well-estimated dates of HIV seroconversion, we showed that HCV incidence significantly increased from 1990 onwards and no decline was observed in recent years. This suggests on-going transmission of HCV among HIV-positive MSM. However, trends seem to differ by geographical region. While HCV incidence appears to have stabilized in Western Europe and remained stable in Southern Europe, a recent increase in HCV incidence was observed in Northern Europe. Interestingly, higher HIV RNA levels, recent HIV infection and younger age were associated with higher HCV incidence. The time from HIV seroconversion to HCV infection has significantly shortened in recent years. Hence, routine and continued surveillance following HIV diagnosis is needed.

The increasing trend in HCV incidence over time is comparable with the trend observed in a recent meta-analysis [2]. We estimated that in 2014 HCV incidence was between 18 and 21/1000 py and in the meta-analysis the extrapolated estimate was 19/1000 py in 2015 [2]. A recent study from EuroSida, not restricted to HIV seroconverters, also reported that HCV incidence differed by European geographical region; Eastern, Northern and Southern Europe had higher odds for HCV seroconversion than Western Europe [19]. Interestingly, no HCV infections were observed among MSM from the Kenyan cohort, while another Kenyan study reported that 10% (30/300) of HIV-positive male and female patients were HCV-coinfected [20]. This might suggest that HCV has not yet been introduced in the Kenyan MSM population. The decline in HCV incidence that we observed after 2009 in Western

1 Europe might be ascribed to earlier introduction or recognition of HCV.
2 Consequently, as previously suggested [3], this might have led to a saturation effect
3 among MSM at higher risk for HCV infection and/or increased HCV awareness,
4 leading to more HCV testing and treatment, as well as safer-sex practices.
5 Conversely, since the introduction of cART, condom use has decreased over time
6 among MSM [21,22], which probably led to the increase in syphilis incidence across
7 European countries in recent years, especially among HIV-positive MSM [23]. In
8 Northern Europe (UK and Norway) HCV incidence seems to have increased in
9 recent years, although the overall effect of calendar year was only significant when
10 method 2 was used. An European survey in 2010 among MSM showed that the
11 prevalence of drug use associated with ‘chemsex’ – i.e., drug use to enhance sexual
12 arousal [24] – was highest in three UK cities [25]; as injecting and non-injecting drug
13 use have been associated with acute HCV among HIV-positive MSM [6,8-10],
14 differences in HCV trends might be partly explained by differences in drug use
15 across European countries. However, we cannot discern whether that study is
16 representative for MSM across Europe. Given the overall continued rise of HCV
17 incidence, HCV-treatment guidelines should consider recommending direct-acting
18 antivirals during acute HCV infection - when registered [26] - to prevent on-going
19 transmission. As suggested by modelling studies, the greatest population benefit
20 among HIV-positive MSM can be achieved when HCV treatment is provided within 1
21 year of HCV diagnosis, together with behavioural interventions [27, 28].

22
23 Furthermore, we found that younger MSM, peaking at around age 35, are at higher
24 risk for HCV infection, in line with findings from the Netherlands [3] but in contrast to
25 a study in the USA, where older MSM had a higher risk of HCV infection [10].

1 Regional differences in the HCV epidemic among HIV-positive MSM could explain
2 this discrepancy, in line with our finding of a borderline significant interaction
3 between age and region.

4
5 HIV RNA was significantly associated with HCV incidence, especially when \log_{10} HIV
6 RNA was ≥ 5 copies/mL. Few studies have assessed the association between HIV
7 RNA and HCV incidence [4,9,12] and, to the best of our knowledge, this is the only
8 study to have modelled HIV RNA as a continuous variable in multivariable analysis.
9 In univariable analyses, two observational cohort studies [4,9] found a significant
10 association between HIV RNA with HCV incidence, whereas a clinical HIV cohort did
11 not [1]. Although, in the Swiss Cohort study, this association was no longer
12 significant in multivariable analysis [4]; but ART use was included in that
13 multivariable model which may mask the effect of HIV RNA as it may lie on the
14 causal pathway. However, in our study, the association between HIV RNA and HCV
15 incidence was attenuated when HIV infection stage was included in the model. The
16 overlap in risk behaviour between HIV and HCV might result in the acquisition of
17 both viruses simultaneously. We found that HCV infection is more likely during
18 recent HIV infection and this is a period characterized by high HIV RNA levels, which
19 might explain the stronger association between HCV incidence and HIV RNA when
20 HIV infection stage is not included in the model. Additionally, until recently, these
21 individuals might not be on cART. Our finding underscores the importance of
22 monitoring HCV incidence and risk factors among HIV seroconverters.

23 Yet HIV RNA remained statistically significant. HIV RNA might partly explain why
24 HIV-positive MSM have a higher risk of HCV infection than HIV-negative MSM [11].

1 The biological mechanism behind the association with HIV RNA may be through the
2 activation of Langerhans cells (LCs) that results in the facilitation of HCV
3 transmission, as immature LCs capture but do not transmit HCV, while activated LCs
4 (due to HIV replication) are able to transmit the virus [29]. Alternatively, having an
5 STI, a risk factor for HCV infection [4,6,9,10,12] leads to an increase in HIV RNA
6 levels [30]. In that case, HIV RNA would be merely a proxy for having an STI. Also,
7 higher HIV RNA levels might be surrogate for poor adherence to cART.
8 Unfortunately, we could not assess the effect of STIs and cART adherence on HCV
9 incidence, as most cohorts do not collect these data.

11 We found no association between HCV incidence and CD4 count, which is in line
12 with most studies [3,4,6,12]. However, one showed that HIV-positive MSM with lower
13 CD4 counts had a higher risk of acquiring HCV [9] while another study only found an
14 association with CD4 count below 500 cell/ μ l [10]. However, both studies did not
15 exclusively include HIV seroconverters and did not account for time since HIV
16 infection.

18 A previous study using data from the CASCADE Collaboration and the same
19 estimating procedures, reported a similar increasing trend in HCV incidence until
20 2007 [1]. However, HCV incidence in 2007 using method 2 was considerably higher
21 than our estimation (51/1000 vs. 21/1000 py); although confidence intervals were
22 wide after 2005 and our estimates fall within this confidence intervals previously
23 estimated [1]. The present study provides a more accurate estimate of HCV

1 incidence after 2000 as additional HCV testing was performed to minimize bias
2 related to selective testing and more MSM were included.

3
4 Our study has some limitations. First, as HCV infection was based on any kind of
5 HCV test, an observed HCV infection might be a re-infection; although 99.1%
6 (334/337) of HCV infections in our study were based on HCV-antibody
7 seroconversion or evidence of acute/recent primary HCV infection. Also, since we
8 lacked data on the mode of HCV transmission, we could not assess whether all HCV
9 infections were sexually transmitted and whether changes in risk behaviour over time
10 (e.g., increase in injecting drug use (IDU)) are driving the HCV epidemic. However,
11 studies have reported HCV acquisition in the absence of traditional HCV risk factors,
12 such as IDU, in the majority of MSM [4,5,7-10,12]. Hence, the increase in sexual risk
13 behaviour among MSM (e.g, condomless anal intercourse [21]) is likely to partly
14 explain the observed trends. Furthermore, although recreational drug use is common
15 among MSM [25], recent studies have reported a low percentage of IDU among HIV-
16 positive MSM with acute HCV infection (5.8% and 12.2%) [6,9]. To the best of our
17 knowledge, evidence of an increase in IDU is scarce as only one study assessed
18 trends in recent years; an increase in IDU, from 45.1% in 2005 to 53.8% in 2014,
19 was observed among HIV-positive MSM reporting methamphetamine use in
20 Australia [31]. Further research is needed to assess changes over time in HCV-
21 related risk factors and the proportion of HCV acquisition attributable to sexual
22 practices and drug use among MSM. Despite the lack of behavioural data, the main
23 focus of our study was to assess temporal trends in HCV incidence, irrespective of
24 the mode of HCV transmission. Furthermore, it is important to bear in mind that
25 clinicians may have monitored patients at risk for HCV infection better over time,

1 leading to more HCV-positive test results in recent years. To account for this
2 possible bias we performed additional HCV testing and we only included data from
3 the date of routine testing onwards. However, the median and mean number of tests
4 was 3 and 4, respectively, over a median follow-up time of 4 years, suggesting that
5 current guidelines [32] might not be followed consistently. This is in line with results
6 from EuroSida where only a median of 3 tests were performed per patient between
7 2002 and 2013 [19]. In addition, due to a lack of country specific HCV testing
8 guidelines (e.g., Italy), HCV testing practices may not be systematic.

9

10 The strengths of our study are that we had data from HIV seroconversion onwards
11 for a large group of MSM, and extensive follow-up that enabled us to assess
12 temporal changes in time from HIV seroconversion to HCV infection and the
13 association between HCV incidence and HIV infection stage. We also applied
14 different estimating methods to calculate HCV incidence and various sensitivity
15 analyses. All methods showed comparable results suggesting that our results are
16 robust.

17

18 To conclude, no decline in HCV incidence was observed in recent years, although
19 trends seem to differ by geographical region. Hence, HCV screening among HIV-
20 positive MSM should be continued and routinely and frequently offered. Furthermore,
21 targeted preventive measures should be implemented and/or scaled-up to decrease
22 the risk of HCV acquisition. Other than recent calendar year, younger age, recent
23 HIV infection and high HIV RNA levels were all associated with HCV incidence.

24

1 **Acknowledgements:**

2 The authors wish to thank all cohort participants for their contribution and EuroCoord
3
4 for funding the CASCADE Collaboration. Also, we wish to thank members from
5
6 CASCADE that contributed to the design of the study: Maria Dorucci, Santiago
7
8 Perez-Hoyos and Roberto Muga. We also want to thank those involved with
9
10 5 additional HCV testing and/or data management support: Petra Blom and Margreet
11
12 6 Bakker (AMC), Paz Sobrino Vegas, and Susana Monge (COR/MAD), Ana Avellón
13
14 7 (CNM, ISCIII), Jamie Inshaw, Anabelle Gourlay and Ashley Olson (UKR), Stefania
15
16 8 Carrara and Alessandro Cozzi-Lepri (ICO), Klaus Jansen (GER), Laurent Tran (PRI),
17
18 9 Martin Rickenbach (SWI) and Nikos Pantazis and Giota Touloumi (AMA). We wish to
19
20 10 convey special thanks to Lorraine Fradette who coordinated and provided logistical
21
22 11 support within CASCADE.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Reference List

Author names **in bold** designate shared co-first authorship

- [1] van der Helm JJ, Prins M, del AJ, Bucher HC, Chene G, Dorrucchi M, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. *AIDS* 2011 May 15;25(8):1083-1091.
- [2] Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. *AIDS* 2015 Nov;29(17):2335-2345.
- [3] Vanhommerig JW, Stolte IG, Lambers FA, Geskus RB, van de Laar TJ, Bruisten SM, et al. Stabilizing incidence of hepatitis C virus infection among men who have sex with men in Amsterdam. *J Acquir Immune Defic Syndr* 2014 Aug 15;66(5):e111-e115.
- [4] **Wandeler G**, Gsponer T, Bregenzer A, Gunthard HF, Clerc O, Calmy A, **Rauch, A** Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. *Clin Infect Dis* 2012 Nov 15;55(10):1408-1416.
- [5] CDC. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men--New York City, 2005-2010. *MMWR Morb Mortal Wkly Rep* 2011 Jul 22;60(28):945-950.
- [6] Apers L, Vanden Berghe W, De WS, Kabeya K, Callens S, Buyze J, et al. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. *J Acquir Immune Defic Syndr* 2015 Apr 15;68(5):585-593.
- [7] Nishijima T, Shimbo T, Komatsu H, Hamada Y, Gatanaga H, Oka S. Incidence and risk factors for incident Hepatitis C infection among men who have sex with men with HIV-1 infection in a large Urban HIV clinic in Tokyo. *J Acquir Immune Defic Syndr* 2014 Feb 1;65(2):213-217.
- [8] Schmidt AJ, Rockstroh JK, Vogel M, An der HM, Baillot A, Krznaric I, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a case-control study. *PLoS One* 2011;6(3):e17781.
- [9] Vanhommerig JW, Lambers FA, Schinkel J, Geskus RB, Arends JE, van de Laar TJ, et al. Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study. *Open Forum Infect Dis* 2015 Sep;2(3):ofv115.
- [10] Witt MD, Seaberg EC, Darilay A, Young S, Badri S, Rinaldo CR, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. *Clin Infect Dis* 2013 Jul;57(1):77-84.
- [11] van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. *AIDS* 2010 Jul 31;24(12):1799-1812.
- [12] Burchell AN, Gardner SL, Mazzulli T, Manno M, Raboud J, Allen VG, et al. Hepatitis C virus seroconversion among HIV-positive men who have sex with men with no history of injection drug use: Results from a clinical HIV cohort. *Can J Infect Dis Med Microbiol* 2015 Jan;26(1):17-22.
- [13] CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. *HIV Med* 2000 Oct;1(4):224-231.
- [14] United Nations (UN). Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other

- groupings. 2016. Retrieved January 10, 2016 from <http://unstats.un.org/unsd/methods/m49/m49regin.htm>
- [15] Vanhommerig JW, Thomas XV, van der Meer JT, Geskus RB, Bruisten SM, Molenkamp R, et al. Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. *Clin Infect Dis* 2014 Dec 15;59(12):1678-1685.
 - [16] Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Muir D, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. *AIDS* 2009 Jan 2;23(1):89-93.
 - [17] R: A language and environment for statistical computing (version 3.2.2, R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>. 2016.
 - [18] StataCorp. 2013. *Stata Statistical Software: Release 13*. College Station, TX: StataCorp LP. 2016.
 - [19] Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio MA, Mitsura VM, et al. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? *Liver Int* 2015 Nov;35(11):2384-2391.
 - [20] Muriuki BM, Gicheru MM, Wachira D, Nyamache AK, Khamadi SA. Prevalence of hepatitis B and C viral co-infections among HIV-1 infected individuals in Nairobi, Kenya. *BMC Res Notes* 2013 Sep 9;6:363.
 - [21] Paz-Bailey G, Mendoza MC, Finlayson T, Wejnert C, Le B, Rose C, et al. Trends in condom use among MSM in the United States: the role of antiretroviral therapy and seroadaptive strategies. *AIDS* 2016 Jul 31;30(12):1985-1990.
 - [22] Jansen IA, Geskus RB, Davidovich U, Jurriaans S, Coutinho RA, Prins M, et al. Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. *AIDS* 2011 Feb 20;25(4):493-501.
 - [23] Abara WE, Hess KL, Neblett FR, Bernstein KT, Paz-Bailey G. Syphilis Trends among Men Who Have Sex with Men in the United States and Western Europe: A Systematic Review of Trend Studies Published between 2004 and 2015. *PLoS One* 2016;11(7):e0159309.
 - [24] Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardo FP. When "chems" meet sex: a rising phenomenon called "ChemSex". *Curr Neuropsychopharmacol* 2016 Nov 17.
 - [25] Schmidt AJ, Bourne A, Weatherburn P, Reid D, Marcus U, Hickson F. Illicit drug use among gay and bisexual men in 44 cities: Findings from the European MSM Internet Survey (EMIS). *Int J Drug Policy* 2016 Oct 24;38:4-12.
 - [26] EASL Recommendations on Treatment of Hepatitis C 2015. *J Hepatol* 2015 Jul;63(1):199-236.
 - [27] **Martin NK, Thornton A**, Hickman M, Sabin C, Nelson M, Cooke GS, et al. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. *Clin Infect Dis* 2016 Feb 16.
 - [28] Salazar-Vizcaya L, Kouyos RD, Zahnd C, Wandeler G, Battegay M, Darling KE, et al. Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. *Hepatology* 2016 Dec;64(6):1856-1869.

- 1 [29] Nijmeijer B, Sarrami Forooshani R, Steba G, Geijtenbeek T.B.H. Immune
2 activation by HIV-1 enhances sexual transmission of HCV. 2016. Presented at
3 the 10th Netherlands Conference on HIV Pathogenesis, Epidemiology and
4 Treatment. Abstract number:08
- 5 [30] Modjarrad K, Vermund SH. Effect of treating co-infections on HIV-1 viral load:
6 a systematic review. Lancet Infect Dis 2010 Jul;10(7):455-463.
- 7 [31] Lea T, Mao L, Hopwood M, Prestage G, Zablotska I, de WJ, et al.
8 Methamphetamine use among gay and bisexual men in Australia: Trends in
9 recent and regular use from the Gay Community Periodic Surveys. Int J Drug
10 Policy 2016 Mar;29:66-72.
- 11 [32] Acute hepatitis C in HIV-infected individuals: recommendations from the
12 European AIDS Treatment Network (NEAT) consensus conference. AIDS
13 2011 Feb 20;25(4):399-409.

Figures titles and legends

Fig. 1: Flow diagram of the study population selection for method 1 and 2 of the HCV incidence analyses

* Becoming at risk being the latest of: enrolment in the cohort, routine HCV testing date per cohort or HIV seroconversion.

** MSM from the French Primo cohort were censored at the 31st of December 2005 as HCV testing was only systematically recorded until that year.

The grey boxes depict MSM whose data were excluded from the analyses.

Fig. 2: HCV incidence among HIV-positive MSM using two methods to estimate follow-up in the CASCADE Collaboration; 1990-2014

Method 1: dashed line, 95%CI: dashed area. Method 2: solid line, 95%CI: grey solid area.

Poisson regression was used to test the overall effect of calendar year on HCV incidence between 1990 and 2014.

Fig. 3: HCV incidence among HIV-positive MSM by European UN geographical region in the CASCADE Collaboration; 1997-2013

Abbreviations: m1= method 1; m2= method 2

Method 1: dashed line, 95%CI: dashed area. Method 2: solid line, 95%CI: grey solid area.

P-values: overall effect of calendar year on HCV incidence between 1997 and 2013 obtained from Poisson regression models.

Fig. 4. HCV incidence by age, CD4 cell count and HIV RNA among HIV-positive MSM from the CASCADE Collaboration, in year 2007 in Western Europe^a

4(A). Incidence by age in years (model 2)^b

4(B). Incidence by CD4 count for an individual with a HIV RNA = 1000, aged 35 (model 3)

4(C). Incidence by HIV RNA for an individual with a CD4 cell count = 500, aged 35 (model 3)

4(D). Incidence by HIV RNA for an individual with a HIV RNA = 1000, aged 35, in the chronic HIV infection stage (model 3)

^a The relative hazards obtained from the regression models were translated into the predicted incidence and this is illustrated for certain values of the covariates (e.g., only for Western Europe).

^b Obtained from model 2 without the interaction term between age and region.

Fig. 5: Time from HIV seroconversion until HCV infection over time: Kaplan-Meier curves by calendar period of HIV seroconversion in the CASCADE Collaboration (1990-2014)^a

^a Curves were truncated when less than 10 individuals were at risk for HCV infection.

The log-rank test was used to assess changes in the time from HIV seroconversion to HCV infection among calendar periods.

Table

| Cohorts | At least one HCV test result | MSM with follow-up ^a & at least one HCV test result | | | At-risk set ^b | | | | Start routine testing date |
|-----------------|------------------------------|--|-------------------|-------------------|--------------------------|---------------|----------|---------------|----------------------------|
| N ^c | n (%) | Total, n (%) | HCV+ ^d | HCV- ^e | Method 1 | | Method 2 | | |
| | | | n (%) | n (%) | n | HCVsc - Pys | n | HCVsc - Pys | |
| Southern Europe | | | | | | | | | |
| AMA; n=177 | 172 (97.2%) | 167 (94.4%) | 2 (1.2%) | 165 (98.8%) | 128 | 0 - 526.3 | 87 | 0 - 347.2 | 1-1-1991 |
| COR; n=365 | 353 (97.7%) | 310 (84.9%) | 5 (1.6%) | 302 (97.4%) | 184 | 3 - 246.2 | 68 | 3 - 87.7 | 1-1-2005 ^f |
| ICO; n=1018 | 914 (89.8%) | 848 (83.3%) | 49 (5.8%) | 770 (90.8%) | 497 | 29 - 1926.3 | 411 | 29 - 1705.7 | AT |
| MAD; n=342 | 308 (90.1%) | 293 (85.7%) | 16 (5.5%) | 274 (93.5%) | 213 | 3 - 1047.9 | 30 | 3 - 56.8 | 1-1-1993 |
| VAL; n=165 | 89 (53.9%) | 85 (51.5%) | 13 (15.3%) | 71 (83.5%) | 65 | 1 - 66.9 | 2 | 1 - 2.9 | 1-1-1998 |
| Total; n=2067 | 1,836 (88.8%) | 1,703 (82.4%) | 85 (5.0%) | 1,582 (92.9%) | 1,087 | 36 - 3813.6 | 598 | 36 - 2200.4 | |
| Western Europe | | | | | | | | | |
| AQU; n=788 | 730 (92.6%) | 707 (89.7%) | 29 (4.1%) | 657 (92.9%) | 486 | 21 - 3053.1 | 360 | 19 - 2389.3 | 1-1-1991 |
| AUS; n=212 | 206 (97.2%) | 201 (94.8%) | 3 (1.5%) | 193 (96.0%) | 181 | 5 - 682.3 | 150 | 4 - 575.7 | 1-1-2006 |
| GER; n=1912 | 1,848 (96.7%) | 1,543 (80.7%) | 63 (4.1%) | 1,393 (90.3%) | 1,025 | 87 - 4557.0 | 764 | 51 - 2665.5 | RT |
| LYO; n=62 | 60 (96.8%) | 59 (95.2%) | 1 (1.7%) | 57 (96.6%) | 11 | 1 - 40.2 | 0 | 0 - 0 | 1-1-1999 ^f |
| NEM; n=239 | 239 (100%) | 239 (100%) | 2 (0.8%) | 215 (90.0%) | 224 | 22 - 1841.6 | 144 | 21 - 1098.1 | RT |
| PRI; n=966 | 894 (92.5%) | 401 (41.5%) | 15 (3.7%) | 381 (95.0%) | 211 | 6 - 791.8 | 190 | 5 - 748.5 | 1-1-1996 ^f |
| SWI; n=343 | 338 (98.5%) | 320 (93.3%) | 4 (1.3%) | 294 (91.9%) | 274 | 22 - 1532.6 | 236 | 17 - 1210.2 | 1-1-2000 |
| Total; n=4522 | 4,315 (95.4%) | 3,470 (76.7%) | 117 (3.1%) | 3,190 (91.9%) | 2,412 | 164 - 12498.5 | 1,844 | 117 - 8687.4 | |
| Northern Europe | | | | | | | | | |
| NOR; n=383 | 378 (98.7%) | 349 (91.1%) | 10 (2.9%) | 328 (94.0%) | 305 | 11 - 2165.9 | 258 | 11 - 1489.6 | 1-1-1995 |
| UKR; n=2714 | 2,209 (81.4%) | 2,073 (76.4%) | 50 (2.4%) | 1,903 (91.8%) | 1,937 | 120 - 9395.2 | 1,582 | 110 - 6871.6 | 1-1-2004 |
| Total; n=3097 | 2,587 (83.5%) | 2,422 (78.2%) | 60 (2.5%) | 2,231 (92.1%) | 2,242 | 131 - 11561.1 | 1,840 | 121 - 8361.2 | |
| North America | | | | | | | | | |
| SAL; n=138 | 138 (100%) | 131 (94.9%) | 4 (3.1%) | 122 (93.1%) | 67 | 5 - 327.2 | 43 | 4 - 230.0 | 1-1-2000 |
| Australia | | | | | | | | | |
| PHA; n=145 | 138 (95.2%) | 138 (95.2%) | 5 (3.6%) | 132 (95.7%) | 133 | 1 - 399.4 | 1 | 1 - 0.8 | 1-1-2002 |
| Total; n=9,969 | 9,014 (90.4%) | 7,864 (78.9%) | 271 (3.4%) | 7,257 (92.3%) | 5,941 | 337- 28599.9 | 4,326 | 279 - 19479.8 | |

Table 1: Number of MSM per cohort with and without HCV test results in the CASCADE Collaboration

Abbreviations: N=number; n=number; HCVsc=HCV seroconverters; PYs=person years of observation; HCV+=HCV-positive; HCV-=HCV-negative; RT=retrospective testing; AT=additional testing only (no routine testing); AMA=AMACS cohort, Greece; AQU: Aquitaine cohort, France; AUS: Austrian HIV cohort study, Austria; COR=CoRis cohort, Spain; GER=German cohort, Germany; IAV=IAVI, Kenya; ICO=ICONA cohort, Italy; LYO= Lyon cohort, France; MAD=Madrid cohort, Spain; NEM=Amsterdam Cohort Study among MSM, the Netherlands; NOR=Oslo and Ullevål hospital cohorts, Norway; PHA=PHAEDRA cohort, Australia; PRI=PRIMO cohort, France; SAL=Southern Alberta Clinic, Canada; SWI=Swiss HIV cohort, Switzerland; UKR=UK Register of HIV seroconverters, UK; VAL=Valencia cohort, Spain; NA=not applicable.

^a MSM with a clinic visit, and thus follow-up, after becoming at risk, being the latest of: enrolment in the cohort, HIV seroconversion or routine testing per cohort. HCV test results irrespective of the moment of becoming at risk.

^b MSM included in the analyses from 1990 until 2014.

^c Number of MSM per cohort irrespective of the moment of becoming at risk, HCV test, year and length of follow-up.


^d HCV-positive MSM without a previous HCV negative test result (i.e., excluding HCV seroconverters).

^e MSM who remained HCV negative throughout follow-up (from becoming at risk until last clinic visit).


^{d,e} Out of all MSM with follow-up & at least one HCV test result (third column).

^f Start of routine testing date before individuals were enrolled in the cohort.




Figure







Figure




Figure







Figure



Number at risk

| | | | | | | |
|-----------|-----|------|------|------|------|-----|
| 1990-1994 | 33 | 83 | 104 | 115 | 143 | 177 |
| 1995-1999 | 57 | 302 | 388 | 420 | 408 | 455 |
| 2000-2004 | 309 | 964 | 1077 | 1076 | 1048 | 955 |
| 2005-2009 | 743 | 1471 | 1514 | 1191 | 831 | 529 |
| 2010-2014 | 383 | 316 | 113 | 12 | 0 | 0 |





Supplementary material

[Click here to download Supplementary material: 201701 Supplement HCVinc.docx](#)

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: coi_disclosure _JdA.pdf](#)

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: coi_disclosure_MP.pdf](#)

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: coi_disclosure _MS.pdf](#)

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: coi_disclosure _RZ.pdf](#)

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: coi_disclosure CB.pdf](#)

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: coi_disclosure DKVS.pdf](#)

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: coi_disclosure JH - RG.pdf](#)

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: coi_disclosure KPorter.pdf](#)

*ICMJE disclosure form

[Click here to download ICMJE disclosure form: 161129 coi_disclosure Daniela_HCV incidence - JH.pdf](#)

***ICMJE disclosure form**

[Click here to download ICMJE disclosure form: coi_disclosure MP.pdf](#)